As of May 31, 2025, Nymox Pharmaceutical Corp (NYMX) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Nymox Pharmaceutical Corp's Forward P/E to Peers
To better understand Nymox Pharmaceutical Corp's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Nymox Pharmaceutical Corp (NYMX) | - |
| Fennec Pharmaceuticals Inc (FENC) | 78.36 |
| Theratechnologies Inc (TH.TO) | 77.87 |
Compared to its competitors, Nymox Pharmaceutical Corp's Forward P/E is difficult to compare due to insufficient data.